Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert S. who wrote (8222)	1/7/1999 8:24:00 AM
From: LLCF	Read Replies (1) \| Respond to of 17367

Continued: XOMA GETS $2 MILLION MILESTONE PAYMENT FROM GENE Based on successful completion of its Phase 2 sturdy with hu1124 antibody product in psoriasis patients. Results from the study will be presented at the first appropriate scientific foorum. DAK

To: Robert S. who wrote (8222)	1/7/1999 9:39:00 AM
From: aknahow	Respond to of 17367

Interesting article Robert. Here is another one on surficants. The problem of catheter related infections is one XOMA patents indicate BPI might also address. 05:01 PM ET 01/06/99 Antibiotics-Coated Catheters Urged Antibiotics-Coated Catheters Urged By The Associated Press= Coating catheters with antibiotics can greatly reduce a major source of infection among hospital patients, researchers say. Catheters are extremely thin, flexible tubes used to introduce drugs, anesthesia or food into a patient via a blood vessel. They may be used for a few hours or remain in place for weeks during treatment for heart disease, cancer and other major diseases. From 150,000 to 200,000 Americans are infected each year when germs are accidentally introduced into the bloodstream by a catheter. An estimated 25 percent die. Some researchers are experimenting with bonding antibacterial agents to catheters to try to cut the rate of infection. A study in Thursday's New England Journal of Medicine compared catheters saturated inside and out with the antibiotics minocycline and rifampin to catheters coated on the outside only with two antibacterial agents _ chlorhexidine and silver sulfadiazine. Only one catheter-related infection occurred among the 350 patients who got catheters impregnated with minocycline and rifampin, compared with 13 among the 370 patients who got catheters coated with chlorhexidine and silver sulfadiazine. Both types of catheters led to lower infection rates than other studies have found in catheters without antibacterial agents. The study was led by Dr. Rabih Darouiche of Baylor College of Medicine in Houston and Dr. Issam Raad of the University of Texas M.D. Anderson Cancer Center. The two men invented the technology for impregnating catheters with minocycline and rifampin and earn royalties as a result.